Hyperforin dicyclohexylammonium salt Hyperforin DCHA|cas:238074-03-8|西域试剂

Hyperforin dicyclohexylammonium salt Hyperforin DCHA,99.52%

产品编号：Bellancom-116330A| CAS NO：238074-03-8| 分子式：C₄₇H₇₅NO₄| 分子量：718.10

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-116330A	￥1200.00	杭州北京（现货）
Bellancom-116330A	￥2000.00	杭州北京（现货）
Bellancom-116330A	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Hyperforin dicyclohexylammonium salt Hyperforin DCHA

产品介绍

贯叶金丝桃素二环己基铵盐 (Hyperforin DCHA) 是瞬时受体典型 6 (TRPC6) 通道激活剂。Hyperforin dicyclohexylammonium salt 通过激活 Ca²⁺ 传导非选择性典型 TRPC6 通道来调节 Ca²⁺ 水平。Hyperforin dicyclohexylammonium salt 还表现出多种药理活性，包括抗抑郁、抗肿瘤、抗痴呆、抗糖尿病等。Hyperforin dicyclohexylammonium salt 调节 γδ T 细胞分泌 IL-17α，改善 Imiquimod (HY-B0180) 诱导的银屑病样小鼠皮肤炎症。

生物活性

Hyperforin dicyclohexylammonium salt (Hyperforin DCHA) is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin dicyclohexylammonium salt modulates Ca²⁺ levels by activating Ca²⁺-conducting non-selective canonical TRPC6 channels. Hyperforin dicyclohexylammonium salt also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin dicyclohexylammonium salt modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model^[4]^[5].

体外研究

Hyperforin dicyclohexylammonium salt 具有多向作用机制。它阻断配体门控 (GABA、NMDA 和 AMPA 受体) 和电压门控通道(Ca²⁺， K⁺， Na⁺) 的电导。
Hyperforin dicyclohexylammonium salt (0.1, 1,10 μM; 2 h) 降低体外培养的小鼠脾 γδ T 细胞中 IL-17A 的表达和分泌。
Hyperforin dicyclohexylammonium salt (0.1, 1,10 μM; 2 h) 抑制 TNF-α 刺激的 HaCaT 细胞中 MAPK 和 STAT3 通路的磷酸化。
Hyperforin dicyclohexylammonium salt (IC₅₀=3.7 μmol/L) 抑制 HDMEC 微血管管的形成和增殖，呈剂量依赖性，无毒性作用^[4]。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	HaCaT cells
Concentration:	0.1, 1, 10 μM; with or without 10, 20 ng/mL TNF-α
Incubation Time:	2 hours
Result:	Reduced the expressions of p-p38, p-ERK, p-JNK, and p-STAT3, especially at the dosage of 10 μM.

体内研究
(In Vivo)

Hyperforin dicyclohexylammonium salt (5 mg/kg; 腹腔注射; 每天 1 次, 共 7 天) 能够改善 Imiquimod (HY-B0180) 诱导的小鼠银屑病皮损情况，抑制炎症细胞浸润和炎症因子释放。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	IMQ-induced psoriasis-like mice model
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; once daily for 7 days
Result:	Significantly ameliorated skin lesion throughout the treatment period, demonstrated by the reduced severity score of skin inflammation. Suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	IMQ-induced psoriasis-like mice model
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; once daily for 7 days
Result:	Significantly ameliorated skin lesion throughout the treatment period, demonstrated by the reduced severity score of skin inflammation. Suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	IMQ-induced psoriasis-like mice model
Dosage:	5 mg/kg
Administration:	Intraperitoneal injection; once daily for 7 days
Result:	Significantly ameliorated skin lesion throughout the treatment period, demonstrated by the reduced severity score of skin inflammation. Suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion.

性状

Solid

溶解性数据

In Vitro:

DMSO : 50 mg/mL (69.63 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.3926 mL	6.9628 mL	13.9256 mL
5 mM	0.2785 mL	1.3926 mL	2.7851 mL
10 mM	0.1393 mL	0.6963 mL	1.3926 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.48 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.48 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。